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doi:10.1016/j.ejvs.2010.04.004Abstract Background: Thrombotic stroke following carotid endarterectomy (CEA) is
preceded by high-grade embolisation (detected using transcranial Doppler (TCD)) and can be
prevented by incremental doses of Dextran. However, this strategy is labour intensive and
Dextran manufacture has now ceased. A randomised trial has suggested that a single 75 mg
dose of Clopidogrel (administered the night before surgery in addition to daily 75 mg Aspirin)
significantly reduces post-CEA embolisation. We hypothesized that this model of dual antipla-
telet therapy might significantly reduce the need for adjuvant Dextran therapy.
Methods: Retrospective audit of prospectively acquired data in 297 patients undergoing CEA
between 01.08.2006 and 30.07.2009. All received routine Aspirin (75 mg daily) in addition to
a single 75 mg dose of Clopidogrel the night before surgery. All underwent completion angio-
scopy and those with a temporal window (n Z 270) underwent intra- and post-operative TCD
monitoring.
Results: High rate embolisation requiring Dextran (>25 emboli in any 10 min period) occurred
in only 1/270 patients (0.4%), significantly less than the 3.2% rate in historical controls where
Clopidogrel was not administered. There were no peri-operative deaths, but 3/297 patients
suffered non-disabling strokes (intra-operative extension of a pre-existing deficit,Professor of Vascular Surgery, Vascular Surgery Group, Division of Cardiovascular Sciences, Clinical
rmary, Leicester, UK. Tel.: þ44 116 2523252; fax: þ44 116 523179.
.nhs.uk (A.R. Naylor).
ty for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
Dual Antiplatelet Therapy Prior to Carotid Endarterectomy 163haemorrhage into lentiform nucleus after hypertensive crisis, contralateral embolic stroke).
The overall 30-day death/stroke rate (1.0%) was not-significantly lower than the 2.6% rate
observed in the preceding 821 patients.
Conclusions: 75 mg Clopidogrel administered the night before surgery (in addition to daily
75 mg Aspirin) was associated with a significant reduction in post-operative embolisation
and Dextran utilisation. No ipsilateral thromboembolic ischaemic events occurred in this
series. As a consequence of this audit, one dose of 75 mg Clopidogrel will continue to be given
pre-operatively (in addition to daily 75 mg Aspirin) and routine post-operative TCD monitoring
has now ceased.
ª 2010 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Introduction
Thrombo-embolic stroke, while being the commonest single
cause of stroke after carotid endarterectomy (CEA), affects
only a small proportion of patients. Previously considered
to be both unpredictable and unpreventable, there is now
compelling evidence that post-operative thromboembolic
stroke is preceded by increasing rates of embolisation
which can be diagnosed using transcranial Doppler (TCD)
ultrasound.1e8 Previous research from this unit has shown
that progression onto stroke in patients with sustained high
rate embolisation can be prevented by incremental Dextran
therapy.9e11 This preventive strategy has worked well in
this Unit from 1995 to 2006 (during which time stroke due to
post-operative thrombotic stroke was virtually abol-
ished10), but it was threatened by a warning that the
production of Dextran was imminently about to cease.12
In anticipation of Dextran’s withdrawal, a review of
practice was undertaken in order to develop an alternative
preventive strategy. Previous research from this unit had
shown that the platelets of patients with higher rate
embolisation were more sensitive to adenosine diphosphate
(ADP).13 Subsequently, a randomised trial found that the
addition of a single 75 mg dose of Clopidogrel (administered
the night before surgery in addition to regular 75 mg
Aspirin) was associated with a significant reduction in post-
operative embolisation, without any increase in haemor-
rhagic complications.14
Accordingly, after 1st August 2006, all patients under-
going CEA received dual antiplatelet therapy (regular 75 mg
Aspirin plus 75 mg Clopidogrel the night before surgery).
Over the next three years, post-operative TCD monitoring
continued (as before) and patients with high rate emboli-
sation (defined as >25 emboli in any 10 min period)
received incremental dose Dextran therapy (while stocks
lasted). The aim of the current study was to audit whether
this novel, dual antiplatelet therapy strategy significantly
reduced post-operative embolisation to the extent that
very few patients would now need Dextran. If proved true,
it might mean that all routine post-operative TCD moni-
toring might become unnecessary.
Materials and Methods
This was a retrospective audit of prospectively acquired
data regarding outcomes in a consecutive series of 298
patients undergoing CEA between 1st August 2006 and 31stJuly 2009. The Leicestershire, Northamptonshire and
Rutland Research Ethics Committee advised that this study
did not fall under the remit of the NHS Research Ethics
Committee as it was audit/service evaluation.Pre-operative assessment
Patients were assessed pre-operatively in a rapid access,
single visit clinic run by Stroke Physicians where risk factor
control and Duplex assessment were performed. Duplex
ultrasound scanning was repeated in all patients prior to
surgery (as recommended by HTA Guidelines15) and all
patients had their TCD window checked. All patients were
commenced on statin therapy (unless contraindicated), but
surgery was not delayed so that it might exert its maximal
benefit. Aspirin (75 mg daily) was continued throughout the
peri-operative period and patients were prescribed a single
75 mg dose of Clopidogrel the night before surgery. This
single 75 mg loading dose of Clopidogrel was used in the
earlier randomised trial after it was found in the work-up
period that higher doses tended to predispose towards
bleeding complications.14,16 If patients were not taking
Aspirin prior to their urgent transfer from the TIA clinic,
they were preloaded with 300 mg Aspirin and then main-
tained on 75 mg daily throughout the peri-operative period.
Prior to planned elective admissions or sometimes following
emergency transfer from the TIA clinic, a small proportion
of patients (5e10%) were found to have been prescribed
alternative antiplatelet strategies The Leicester Vascular
Unit had developed its own policy for dealing with this issue
as there were concerns (amongst the surgeons) that
patients could potentially receive excessive peri-operative
antiplatelet and heparin therapy that could increase the
risk of haemorrhagic complications. Accordingly, wherever
possible, patients receiving chronic Clopidogrel therapy
had this medication stopped five days pre-operatively.
A single 75 mg dose of Clopidogrel was then administered
the night before surgery. Some patients were prescribed
Aspirin and Dipyridamole prior to their admission. Because
Dipyridamole is only a weak ADP inhibitor, this medication
was stopped 48 h pre-operatively and patients were then
prescribed 75 mg Clopidogrel the night before surgery.
Patients taking warfarin had this medication stopped 3e4
days pre-operatively (unless contraindicated). They were
commenced on Aspirin (300 mg loading dose, 75 mg daily)
and then administered 75 mg Clopidogrel the night before
CEA. Warfarin was restarted after surgery.
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The operative procedure has remained essentially
unchanged since 1991 (general anaesthesia, routine patch-
ing, routine shunting, systemic heparinisation (unfractio-
nated) and distal intimal tacking sutures),17 although amuch
greater proportion of symptomatic patients now undergo
surgery within 14 days of suffering their index event. In
patients with an accessible transtemporal window, TCD
monitoring was commenced following induction of general
anaesthesia using a fixed 2 MHz head probe, which was pro-
tected by a semi-circular headguard. The surgeon and
anaesthetist aimed to ensure that mean blood flow velocity
in the middle cerebral artery (MCAV) was >15 cm/s at all
times. This threshold of 15 cm/s was chosen because Halsey
has previously shown this to correlate with loss of cerebral
electrical activity18 and it has worked well in several
previous prospective audits in the past.9,10,12 If theMCAVwas
<15 cm/s following shunt insertion, the shunt was reposi-
tioned to exclude abutment against the distal ICA lumen. If
the MCAV still remained <15 cm/s, blood pressure was
therapeutically elevated by the anaesthetist. Immediately
prior to completing patch closure, a 5mmspacewas retained
adjacent to the orifice of the external carotid artery. The
shunt was removed and all vessels were back vented and
irrigated with heparinised saline. The lumen of the endar-
terectomy zone was then inspected with a flexible hystero-
scope (Olympus 1070-48,). Our policy has been to repair all
intimal flaps >3 mm and aspirate any residual thrombi from
the lumen.10Table 1 Patient demographics.
Males 204 (69%)
Females 93 (31%)








Unilateral >70% 241 (81%)
Bilateral >70% 27 (9%)
Contralateral occlusion 29 (10%)Post-operative monitoring
Following recovery from anaesthesia, the patient was
transferred through to the recovery area of the operating
theatre. The head probe was then reconnected in order to
allow post-operative TCD monitoring. Prior to 1st August
2006, all patients underwent 3 h of TCD monitoring.
However, following a review of practice in 821 patients
with a TCD window,12 it was noted that if the patient had 10
or fewer emboli detected in the first 30 min of monitoring in
Theatre Recovery no-one went on to require Dextran. By
contrast, patients with 11þ emboli had a 20% chance of
needing Dextran. Accordingly, after August 2006, all
patients with an accessible TCD window underwent 30 min
of TCD monitoring in Theatre Recovery. If the total embolus
count was 10 or less during this time, TCD monitoring was
then stopped. If, however, 11 emboli were detected, TCD
monitoring was extended for a further 60 min.
The Vascular Technologists were experienced in TCD
monitoring and used the 1995 consensus criteria for iden-
tifying emboli.19 Previous work in this department has
shown that emboli detected in the early post-operative
period are exclusively particulate.20 The decision to
prescribe Dextran has remained unchanged since October
1995. Dextran 40 (Pharmacia Ltd, Milton Keynes, England)
was administered to any patient who had 25 emboli in any
10 min period. The threshold of 25 emboli per 10 min
period was based on work from Gaunt’s pilot study.17 During
the latest study, intravenous Dextran was administered as
a 30 ml bolus followed by an intravenous infusion starting at30 ml/h (previously it had been a 20 ml bolus followed by an
infusion rate of 20 ml/h). The Dextran infusion rate was
increased stepwise every 10 min to a maximum of 50 ml/h if
there was no reduction in the rate of embolisation. Once
the rate of embolisation stabilised or reduced, Dextran was
continued at that dose for a further 12 h. Our protocol
required that any patient who required Dextran then
underwent continued TCD monitoring until their embolisa-
tion was controlled.
Patients were usually discharged on day two taking
regular Aspirin therapy (75 mg daily). No further Clopidog-
rel (other than the single 75 mg dose given the night before
surgery) was administered unless this was mandated for
other reasons (e.g. cardiac indication etc). All patients
were reviewed in the Outpatient Department for 4e6
weeks following surgery.
Control group
This was not a randomised controlled trial and we therefore
used the 821 patients with an accessible TCD window who
underwent CEA during the immediately preceding period
(1995e2006) as historical controls.12 We accept this to be
a limitation to this study. However, while more emergency
procedures will have been performed in the later study
period, no other systematic differences in patient selection
criteria or operative/monitoring techniques took place. As
was indicated earlier, the simple aim of this study was to
see whether this novel, dual antiplatelet therapy strategy
significantly reduced post-operative embolisation to the
extent that very few patients would now need Dextran.
Results
Between 1st August 2006 and 31st July 2009, 298 patients
underwent CEA. One patient did not receive Clopidogrel
and was excluded from analysis. Table 1 summarises the
basic patient data in the 297 patients who will comprise the
denominator in any statistics regarding clinical outcome.
The majority (n Z 204) were male (69%), while 93 were
female (31%). Mean age of the overall cohort was 69 years.
In line with recent trends in practice, an increasing
minority (35%) underwent either expedited or emergency
CEA. The majority of patients (85%) reported carotid
Dual Antiplatelet Therapy Prior to Carotid Endarterectomy 165territory symptoms within the preceding 6 months and only
44 (15%) were neurologically asymptomatic. Most patients
undergoing CEA had a unilateral carotid stenosis >70%
(81%), 27 (9%) had bilateral severe carotid stenoses >70%,
while 29 (10%) had a symptomatic stenosis >70% and
a contralateral occlusion. Completion angioscopy was
undertaken in 289 patients (97.3%). This was normal in 270
(93.4%), residual luminal thrombus was aspirated in 16
patients (5.5%), while 3 patients (1%) underwent repair of
a distal intimal flap.
Two hundred and seventy patients (91%) had an acces-
sible temporal window for TCD and will comprise the
denominator for any statistics regarding embolisation and
Dextran usage. Table 2 details the actual magnitude of
post-operative embolisation, the need for extended TCD
monitoring beyond 30 min in Theatre Recovery (i.e. 11 or
more emboli detected in the first 30 min) and the
requirement for Dextran. Parallel data for the 1995e2006
historical control are also provided for comparison.
Between 1995 and 2006, 694/821 patients (85%) had 10
or fewer emboli detected in the first 30 min in Theatre
Recovery (85%). In the cohort of patients receiving a single
75 mg dose of Clopidogrel the night before surgery
(in addition to daily 75 mg Aspirin), this proportion
increased to 96.3% (260/270, p < 0.0001). Accordingly, the
proportion of patients with 11þ emboli detected (and who
therefore qualified for an extended period of TCD moni-
toring) fell significantly from 15% in patients undergoing
CEA in the period 1995e2006 to 3.7% in those receiving the
novel model of dual antiplatelet therapy (p < 0.0001). Not
one patient in the current audit had >100 emboli detected
in the first 30 min in Theatre Recovery, compared with 1% in
the historical cohort. The incidence of high rate embolisa-
tion requiring intravenous Dextran (defined as >25 emboli
detected in any 10 min period) fell significantly from 3.2%
(n Z 26) in those undergoing CEA between 1995 and 2006,
to only one patient (0.4%) in those receiving Aspirin and
Clopidogrel (p Z 0.0062).
There were no post-operative deaths, but three patients
(1%) suffered a stroke within 30 days of surgery. One
recovered from anaesthesia with extension of his pre-
operative neurological deficit. He had presented with
a disabling stroke with partial recovery and scored 3 on the
modified Rankin scale21 at the time of his expedited CEA
(8 days post stroke). Ordinarily, we would have deferred
surgery for 4e6 weeks in patients scoring 3 on the modi-
fied Rankin scale, but he suffered two further neurologicalTable 2 Magnitude of Post-operative embolisation and requirem
Post-op TCD monitoring 1995e2
Aspirin
n Z 821




>30 min TCD monitoring required in Recovery 27 (15%
Number needing Dextran 26 (3.2
* The historical data from 1995 to 2006 were derived from Sharpe et
** Two tailed Fisher’s Exact Test.events prior to surgery and had ongoing embolisation on
TCD. Unfortunately, it proved impossible to insert a shunt
after carotid clamping and it is likely that his stroke was
secondary to haemodynamic injury to the ischaemic
penumbra surrounding his recent cerebral infarct. Post-
operative duplex scanning revealed no abnormality, while
a CT scan showed no evidence of haemorrhage. By 30-days,
his disability was classified as non-disabling following
independent assessment by our stroke physicians. The
second (non-disabling) stroke occurred 18 h post-opera-
tively and followed haemorrhage into the lentiform nucleus
after a hypertensive crisis. The third (non-disabling) stroke
occurred in the contralateral (i.e. non-operated) hemi-
sphere at 24 days. While being definitely embolic in aeti-
ology (recent cortical infarction on CT scan), it remains
unknown whether this followed embolism from a cardiac
source or from the 40% stenosis in the non-operated artery.
In this series, no patient suffered an ipsilateral, throm-
boembolic ischaemic event in the post-operative period
and only three patients (1%) required re-exploration for an
expanding cervical wound haematoma.Discussion
This audit is the latest in a series of themed projects aimed
at reducing the risk of stroke both during and after carotid
endarterectomy (CEA). Previous work has shown that intra-
operative stroke (i.e. apparent upon recovery from anaes-
thesia) can be prevented by targeted quality control
measures.10,22 In our experience, the commonest single
cause of intra-operative stroke is embolisation of retained
luminal thrombus (derived from bleeding from the trans-
ected vasa vasorum in the endarterectomy zone) which is
easily diagnosed using completion angioscopy.10,22 In this
latest study, only one patient (0.3%) recovered from
anaesthesia with a new neurological deficit and this was
thought to be secondary to haemodynamic injury to the
ischaemic penumbra surrounding the recent area of cere-
bral infarction as we had been unable to insert a shunt.23
Following an uneventful recovery from anaesthesia,
peri-operative stroke can follow cardiogenic embolism,
hyperperfusion syndrome or intracranial haemorrhage, but
the single most common cause (especially in the first 6 post-
operative hours) is thromboembolism from thrombus
accumulating within the endarterectomy zone.1e8 This can






) 260 (96.3%) p < 0.0001**
) 10 (3.7%)
) 0 (0%)
) 10 (3.7%) p < 0.0001**
%) 1 (0.4%) p Z 0.0062**
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stroke was considered unpreventable. However, a number
of studies (together with a meta-analysis of published data)
have now clearly shown that post-operative thromboem-
bolic strokes are preceded by increasing rates of emboli-
sation that can be detected using TCD.1e8 These studies
consistently show that about 3e5% of patients develop high
rate embolisation in the first few hours after endarterec-
tomy and that approximately 50% will go on to suffer
a thromboembolic stroke.1e8
With increasing awareness of the association between
increasing embolisation and post-operative stroke, a number
of therapeutic strategies have been developed to either
prevent or treat the small number of patients with
increasing embolisation who will, otherwise, be at high risk
of suffering a stroke. These strategies include the use of
Dextran,10,11 S-nitroso-glutathione24 and, more recently,
Tirofiban.25 The most commonly used agent, however, is
Dextran and this has been the preferred therapeutic agent in
this unit since 1995. During this time, a policy of routine
post-operative TCD monitoring combined with selective
Dextran therapy in patients with >25 emboli in any 10 min
period of TCD monitoring has virtually abolished post-oper-
ative thromboembolic stroke and, in particular, no patient
has undergone re-exploration for stroke due to early carotid
thrombosis since 1995.9,10,12 Interestingly, despite a general
assumption that Dextran exerts its beneficial effect through
its assumed antiplatelet and rheological properties,
evidence suggests that Dextran is probably exerting most of
its beneficial effect by increasing plasmin levels through
Dextran blockade of tPA uptake leading to enhanced fibri-
nolysis, whilst also reducing platelet adhesion to von Wille-
brand Factor and platelet activation by thrombin26
Notwithstanding these new ideas about Dextran’s prin-
ciple mode of action, it is indisputable that routine post-
operative TCD monitoring is highly labour intensive. As
a consequence, we undertook a review of practice in early
2006 and analysed post-operative TCD data in 821 CEA
patients with an accessible TCD window and who had highly
accurate data regarding the magnitude of embolisation in
the first 30 min in Theatre Recovery.12 This review was
primarily driven by anecdotal reports from the Vascular
Technologists that most patients destined to require
Dextran could be identified within the first 30 min of
monitoring. The review of practice showed that if 10 or
fewer emboli were detected in the first 30 min of starting
monitoring in Theatre Recovery, no patient went on to
require Dextran. However, if the embolus count exceeded
11, 20% went on to require Dextran therapy, of whom 54%
would require an increase in their Dextran dose in order to
control high rates of embolisation. As a consequence of this
review, it was decided to revise the monitoring protocol.
TCD monitoring would now stop after 30 min if 10 of fewer
emboli were detected es, while monitoring would continue
in patients with 11 or more emboli detected. Given the
findings of the historical review (Table 2), it was antici-
pated that this would reduce the need for extended post-
operative by 85%.12 This, in itself, represented a significant
reduction in workload to our Vascular Studies colleagues.
However, within months of completing this review, it
was announced that one of the main Dextran manufacturers
was ceasing production. In anticipation of this, analternative approach to preventing post-operative throm-
boembolic stroke was revisited. In the past, it had been
assumed that most post-operative thromboembolic strokes
followed inadvertent technical error. However by 2002,
research suggested that a considerable proportion may
actually be ‘patient mediated’. For example, patients
undergoing staged bilateral CEAs had similar rates of
embolisation after each procedure27; i.e. if you were
a higher rate emboliser after the first CEA, you were more
likely to be a higher rate emboliser after the second.
Second, patients undergoing re-exploration for post-oper-
ative carotid thrombosis tended to have platelet rich
thrombus that was adherent to the endarterectomy zone in
the absence of technical error.17 Third, patients rando-
mised to vein patch closure had identical rates of post-
operative, high rate embolisation, compared to those
randomised to prosthetic patch angioplasty.28 Finally (and
most importantly), the platelets of patients with higher
rates of embolisation after CEA were more sensitive to
stimulation by ADP using platelet aggregometry and flow
cytometry.13 In a subsequent randomised trial, Payne
demonstrated that patients taking regular Aspirin and who
were then randomised to receive a single 75 mg dose of
Clopidogrel the night before surgery had significantly fewer
emboli detected in the first 3 h after surgery than those
who were randomised to regular 75 mg Aspirin (plus
placebo the night before).14 In addition, combination
Aspirin and Clopidogrel was not associated with an increase
in bleeding complications, although the time from resto-
ration of flow to removal of the surgical drapes (an indirect
marker of securing haemostasis at the patch) was 20 min
longer in the Clopidogrel group.14
Accordingly, once warned that Dextran production
would cease in the near future, it was decided to test the
hypothesis (in a larger cohort of patients than was used in
Payne’s randomised trial) that the administration of
a single 75 mg dose of Clopidogrel the night before surgery
(in addition to daily 75 mg Aspirin) would significantly
reduce post-operative embolisation to the extent that very
few patients would now need Dextran.
Over the three-year period, all patients (bar one)
received dual antiplatelet therapy prior to CEA. There was
no observed increase in bleeding complications, but
surgeons continued to observe that they had to press for
a longer period of time in order to secure haemostasis. This
cannot be avoided. However, compared with historical
controls, this minor inconvenience was offset by; (i)
a significant reduction in the proportion of patients with
>10 emboli detected in the first 30 min of TCD monitoring
in Theatre Recovery (3.7% vs 15%), (ii) the need for
extended monitoring beyond 30 min (3.7% vs 15%) and,
more importantly, (iii) a highly significant reduction in the
incidence of high rate embolisation requiring Dextran
therapy (0.4% vs 3.2%). Patients receiving dual antiplatelet
therapy prior to CEA had a non-significant reduction in the
30-day risk of death/stroke (1% vs 2.6%), although this audit
was never powered to show a significant reduction in the
overall peri-operative risk.
In conclusion, this audit has shown that (notwithstanding
the absence of a contemporary control group), a sin-
gle75 mg dose of Clopidogrel administered the night before
surgery all but abolished the need for adjuvant Dextran
Dual Antiplatelet Therapy Prior to Carotid Endarterectomy 167therapy and no patient in this series suffered an ipsilateral
thromboembolic stroke. Only one patient developed high
rate embolisation and required Dextran (which may of
course be attributable to resistance), but it would have
been unrealistic to assume that this antiplatelet strategy
would completely abolish all embolisation. However, given
that 50% of patients with high rate embolisation will go onto
suffer a thromboembolic stroke, our latest data would
suggest that we would now have to monitor almost 600
patients with TCD in the early post-operative period in
order to identify the two patients with high rate emboli-
sation who would need Dextran in order to prevent one
post-operative thromboembolic stroke. That is clearly
impractical. Accordingly, after 15 years, routine post-
operative TCD monitoring has now ceased. All patients will
continue to receive dual antiplatelet therapy prior to
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